Our broad portfolio consists of multiplex panels that allow you to choose, within the panel, analytes that best meet your needs. On a separate tab you can choose the premixed cytokine format or a single plex kit.
Cell Signaling Kits & MAPmates™
Choose fixed kits that allow you to explore entire pathways or processes. Or design your own kits by choosing single plex MAPmates™, following the provided guidelines.
The following MAPmates™ should not be plexed together:
-MAPmates™ that require a different assay buffer
-Phospho-specific and total MAPmate™ pairs, e.g. total GSK3β and GSK3β (Ser 9)
-PanTyr and site-specific MAPmates™, e.g. Phospho-EGF Receptor and phospho-STAT1 (Tyr701)
-More than 1 phospho-MAPmate™ for a single target (Akt, STAT3)
-GAPDH and β-Tubulin cannot be plexed with kits or MAPmates™ containing panTyr
.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Select A Species, Panel Type, Kit or Sample Type
To begin designing your MILLIPLEX® MAP kit select a species, a panel type or kit of interest.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
This item has been added to favorites.
Species
Panel Type
Selected Kit
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
96-Well Plate
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
Add Additional Reagents (Buffer and Detection Kit is required for use with MAPmates)
Qty
Catalogue Number
Ordering Description
Qty/Pack
List Price
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
Space Saver Option Customers purchasing multiple kits may choose to save storage space by eliminating the kit packaging and receiving their multiplex assay components in plastic bags for more compact storage.
This item has been added to favorites.
The Product Has Been Added To Your Cart
You can now customize another kit, choose a premixed kit, check out or close the ordering tool.
[1] Liu D, Ren T, Gao X. Cationic Transfection Lipids, Current Medicinal Chemistry. 2003; 10(14): 1307‐1315
[2] Wattiaux R, Jadot M, Warnier‐Pirotte MT, Wattiaux‐De Coninck S. Cationic Lipids Destabilize Lysosomal Membrane in vitro. FEBS Letter. 1997; 417(2): 199‐202
[3] Xu Y, Szoka FC. Mechanism of DNA Release from Cationic Liposome/DNA Complexes used in Cell Transfection. Biochemistry. 1996; 35(18): 5616‐5623
[4] Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, Border R, Ramsey P, Martin M, Felgner PL. Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations. J. Biol. Chem.1994; 269(4): 2550‐2561
[5] Heyes JA, Niculescu‐Duvaz D, Cooper RG, Springer CJ. Synthesis of Novel Cationic Lipids: Effect of Structural Modification on the Efficiency of Gene Transfer. J. Med. Chem. 2002; 45(1): 99‐114
[6] Hirko A, Tang F, Hughes JA. Cationic Lipid Vectors for Plasmid DNA Delivery. Current Medicinal Chemistry. 2003; 10(14): 1185‐1193
[7] Felgner PL. Nonviral Strategies for Gene Therapy. Sci. Am. 1997; 276(6), 102‐106
[8] Remy JS, Sirlin C, Vierling P, Behr JP. Gene Transfer with a Series of Lipophilic DNA‐binding molecules. Bioconjugate Chem. 1994; 5, 647‐654
[9] Platscher M. DOTAP Enantiomers, Racemic and Enantiomerically Pure DOTAP Chloride. Merck Eprova AG.2008; presentation
[10] Terp MC, Bauer F, Sugimoto Y, Yu B, Brueggemeier RW, Lee LJ, Lee, RJ. Differential Efficacy of DOTAP Enantiomers for siRNA Delivery in vitro. Int J Pharm. 2012; 430: 328‐334
[11] Hays LM, Crowe JH, Wolkers W, Rudenko S. Factors Affecting Leakage of Trapped Solutes from Phaospholipid Vesicles during Thermotropic Phase Transitions. Cryobiol. 2001; 42: 88‐102
[12] Vasievich EA, Chen W, Huang L. Enantiospecific Adjuvant Activity of Cationic Lipid DOTAP in Cancer Vaccine. Cancer Immunol Immunother. 2011; 60: 629‐638
[13] Vasievich EA, Ramishetti S, Zhang Y, Huang L. Trp2 Peptide Vaccine Adjuvant with (R)‐DOTAP Inhibits Tumor Growth in an Advanced Melanoma Model. Mol Pharmaceutics. 2012; 9(2): 261‐268